Study of Food Effects of VV261 Tablets in Healthy Trial Participants
NCT07927218, Phase 1, Not yet recruiting, Vigonvita Life Sciences
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Study of Food Effects of VV261 Tablets in Healthy Trial Participants | ClinicalTrials.gov |
| NCT number | NCT07927218 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Phase 1 | ClinicalTrials.gov |
| Enrollment | 15 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Vigonvita Life Sciences | ClinicalTrials.gov |
| Conditions | Severe Fever With Thrombocytopenia Syndrome | ClinicalTrials.gov |
| Interventions | VV261, VV261, VV261 | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Cmax | Baseline to 96 hours after the last administration | Maximum observed plasma concentration | ClinicalTrials.gov |
| Primary | Tmax | Baseline to 96 hours after the last administration | Time at which Cmax occurs | ClinicalTrials.gov |
| Primary | AUC0-t | Baseline to 96 hours after the last administration | Area under the plasma concentration time curve from time zero to the last measurable concentration | ClinicalTrials.gov |
| Primary | AUC0-∞ | Baseline to 96 hours after the last administration | Area under the plasma concentration-time curve from time zero to infinity | ClinicalTrials.gov |
| Primary | t1/2 | Baseline to 96 hours after the last administration | Half life of elimination | ClinicalTrials.gov |
| Primary | CL/F | Baseline to 96 hours after the last administration | Apparent clearance | ClinicalTrials.gov |
| Primary | mean Resident Time | Baseline to 96 hours after the last administration | Mean Resident Time from time zero to infinity/the last | ClinicalTrials.gov |
| Primary | Vd/F | Baseline to 96 hours after the last administration | Apparent volume of distribution during the terminal phase | ClinicalTrials.gov |
| Primary | Incidence of Treatment-Emergent Adverse Events | Baseline to 7days after the last administration | Incidence of Treatment-Emergent Adverse Events | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)